Akash Tewari
Stock Analyst at Jefferies
(4.75)
# 616
Out of 4,456 analysts
481
Total ratings
57.7%
Success rate
14.4%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintained: Buy | $35 → $34 | $24.29 | +39.98% | 43 | Jun 23, 2026 | |
| ALKS Alkermes | Maintained: Buy | $58 → $59 | $55.08 | +7.12% | 27 | Jun 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $172 → $181 | $168.52 | +7.41% | 27 | Jun 16, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $95 → $98 | $87.89 | +11.50% | 4 | Jun 16, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $113 | $81.18 | +39.20% | 8 | Jun 15, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,330 → $1,350 | $1,208.12 | +11.74% | 43 | Jun 9, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $138 | $91.22 | +51.28% | 37 | Jun 1, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $16 → $40 | $22.00 | +81.82% | 2 | Jun 1, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $180 | $127.88 | +40.76% | 2 | May 22, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $113 → $104 | $59.00 | +76.27% | 36 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $785.40 | - | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $4.26 | +228.64% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $885 → $890 | $632.90 | +40.62% | 35 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $358.33 | -2.32% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $282 → $580 | $491.34 | +18.04% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $980 → $1,008 | $887.18 | +13.62% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $46 | $54.77 | -16.01% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $35 | $18.56 | +88.58% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $42 | $24.15 | +73.91% | 6 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $14.00 | +42.86% | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $82.19 | -2.66% | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $398 → $502 | $512.65 | -2.08% | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 → $96 | $132.55 | -27.57% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $138 | $128.66 | n/a | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $8.00 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $68 | $57.52 | n/a | 13 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $183 | $230.02 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.5 | $4.04 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $18.56 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.68 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $16.33 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.77 | n/a | 2 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9 | $33.21 | n/a | 1 | Jul 19, 2019 |
Pfizer
Jun 23, 2026
Maintained: Buy
Price Target: $35 → $34
Current: $24.29
Upside: +39.98%
Alkermes
Jun 18, 2026
Maintained: Buy
Price Target: $58 → $59
Current: $55.08
Upside: +7.12%
Neurocrine Biosciences
Jun 16, 2026
Maintained: Buy
Price Target: $172 → $181
Current: $168.52
Upside: +7.41%
Spyre Therapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $95 → $98
Current: $87.89
Upside: +11.50%
Ionis Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $113
Current: $81.18
Upside: +39.20%
Eli Lilly and Company
Jun 9, 2026
Maintained: Buy
Price Target: $1,330 → $1,350
Current: $1,208.12
Upside: +11.74%
BioNTech SE
Jun 1, 2026
Maintained: Buy
Price Target: $138
Current: $91.22
Upside: +51.28%
Jade Biosciences
Jun 1, 2026
Maintained: Buy
Price Target: $16 → $40
Current: $22.00
Upside: +81.82%
Gilead Sciences
May 22, 2026
Maintained: Buy
Price Target: $180
Current: $127.88
Upside: +40.76%
BioMarin Pharmaceutical
May 21, 2026
Maintained: Buy
Price Target: $113 → $104
Current: $59.00
Upside: +76.27%
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $785.40
Upside: -
Apr 30, 2026
Maintained: Buy
Price Target: $14
Current: $4.26
Upside: +228.64%
Mar 11, 2026
Maintained: Buy
Price Target: $885 → $890
Current: $632.90
Upside: +40.62%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $358.33
Upside: -2.32%
Mar 10, 2026
Initiated Coverage: Buy
Price Target: $282 → $580
Current: $491.34
Upside: +18.04%
Feb 19, 2026
Maintained: Buy
Price Target: $980 → $1,008
Current: $887.18
Upside: +13.62%
Dec 11, 2025
Maintained: Buy
Price Target: $50 → $46
Current: $54.77
Upside: -16.01%
Dec 5, 2025
Maintained: Buy
Price Target: $26 → $35
Current: $18.56
Upside: +88.58%
Nov 17, 2025
Maintained: Buy
Price Target: $13 → $42
Current: $24.15
Upside: +73.91%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $14.00
Upside: +42.86%
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $82.19
Upside: -2.66%
Aug 12, 2025
Maintained: Buy
Price Target: $398 → $502
Current: $512.65
Upside: -2.08%
Jul 8, 2025
Maintained: Buy
Price Target: $86 → $96
Current: $132.55
Upside: -27.57%
Jun 18, 2025
Maintained: Buy
Price Target: $138
Current: $128.66
Upside: n/a
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $8.00
Upside: n/a
Apr 23, 2025
Maintained: Buy
Price Target: $70 → $68
Current: $57.52
Upside: n/a
Apr 1, 2025
Maintained: Buy
Price Target: $183
Current: $230.02
Upside: n/a
Jan 29, 2025
Maintained: Hold
Price Target: $6 → $2.5
Current: $4.04
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $18.56
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $1.68
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $16.33
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $6.77
Upside: n/a
Jul 19, 2019
Initiated Coverage: Hold
Price Target: $9
Current: $33.21
Upside: n/a